

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	To be assigned
				Filing Date	April 2, 2004
				First Named Inventor	Peeters et al.
				Group Art Unit	(presumed) 1648
				Examiner Name	(presumed) S. Foley
				Attorney Docket Number	2183-4646.2US
Sheet	1	of	8		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SH		#EP 0780475 A1	08-09-1995	Schweiz, Serum- & Impfstitut Bern		
SN		#EP 0702085 A1	03-20-1996	Akzo Nobel N.V.		
SH		#WO 99/66045	12-23-1999	Stichting Dienst Landbouwkundig Onderzoek		

Examiner Signature		Date Considered	8-4-2006
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	April 2, 2004
		First Named Inventor	Peeters et al.
		Group Art Unit	(presumed) 1648
		Examiner Name	(presumed) S. Foley
Sheet	2	of	8
		Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Pokric et al., Vaccine, 1993, pp. 655-59, Vol. 11, No. 6.	
SH		#Fields et al., Virology, 3rd edition, 1995, pp. 1181-87, Vol. 1, Lippencott Williams and Wilkins, Philadelphia, USA.	
SH		#Vindevoel et al., "Panzootic Newcastle Disease Virus in Pigeons," undated, pp. 184-196.	
SH		#Spradbrow, P. B., "Geographical Distribution," undated, pp. 247-255.	
SH		#Rott et al., "Molecular Basis of Infectivity and Pathogenicity of Newcastle Disease Virus," undated, pp. 98-113.	
SH		#Peeples, Mark E., "Newcastle Disease Virus Replication," undated, pp. 45-79.	
SH		#Kaleta et al., "Newcastle Disease in Free-Living and Pet Birds," undated, pp. 197-246.	
SH		#Hanson, Robert P., "Heterogeneity within Strains of Newcastle Disease Virus: Key to Survival," undated, pp. 113-131.	
SH		#Doyle, T. M., "A Hitherto Unrecorded Disease of Fowls Due to a Filter-Passing Virus," undated, pp. 144-169.	
SH		#Beaudette et al., "Newcastle Disease Immunization with Live Virus," undated, pp. 302-334.	
SH		#Beard et al., "Newcastle Disease," undated, Chapter 19, pp. 452-470.	
SH		#Alexander, D. J., "Paramyxovirus Infection," Virus infections of birds, undated, Chapter 22, pp. 321-340.	
SH		#Hitchner et al., "A Virus of Low Virulence for Immunizing Fowls against Newcastle Disease," December 1948, pp. 525-530.	

Examiner Signature	Sharon	Date Considered	8-4-2006
-----------------------	--------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	April 2, 2004
		First Named Inventor	Peeters et al.
		Group Art Unit	(presumed) 1648
		Examiner Name	(presumed) S. Foley
Sheet	3	of	8
		Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Hofstad, M. S., "Immunization of Chickens Against Newcastle Disease by Fomalin-Inactivated Vaccine," October 1953, pp. 586-589.	
SH		#Heuschele et al., "Local Immunity and Persistence of Virus in the Tracheas of Chickens Following Infection with Newcastle Disease Virus," May 1970, Vol. 121, No. 5, pp. 497-504.	
SH		#Smith et al., "Isolation and Assay of Rabies Serogroup Viruses in CER Cells," 1977, <u>Intervirology</u> , Vol. 8, pp. 92-99.	
SH		#Moscovici, Carlo, "Continuous Tissue Culture Cell Lines Derived from Chemically Induced Tumors of Japanese Quail," May 1977, <u>Cell</u> , Vol. 11, pp. 95-103.	
SH		#Madansky et al., "Noncytopathic Mutants of Newcastle Disease Virus," June 1978, Vol. 26, No. 3, pp. 724-729.	
SH		#Chang et al., "Construction and Characterization of Amplifiable Multicopy DNA Cloning Vehicles Derived from the P15A Cryptic Miniplasmid," June 1978, Vol. 134, No. 3, pp. 1141-1156.	
SH		#Goldhaft, Tevis M., "Guest Editorial Historical Note on the Origin of the LaSota Strain of Newcastle Disease Virus," October 1, 1979, <u>Avian Diseases</u> , Vol. 24, No. 2, pp. 297-301.	
SH		#Garten et al., "Mutational Changes of the Protease Susceptibility of Glycoprotein F of Newcastle Disease Virus: Effects on Pathogenicity," 1980, <u>J. Gen. Virol.</u> , Vol. 50, pp. 135-147.	
SH		#Madansky et al., "Noncytopathic Mutants of Newcastle Disease Virus Are Defective in Virus-Specific RNA Synthesis," January 1981, <u>Journal of Virology</u> , Vol. 31, No. 1, pp. 317-327.	
SH		#Madansky et al., "Relationship Among Virus Spread, Cytopathogenicity, and Virulence as Revealed by the Noncytopathic Mutants of Newcastle Disease Virus," December 1981, <u>Journal of Virology</u> , Vol. 40, No. 3, pp. 691-702.	
SH		#Cho, B. R., "Cytopathic Effects and Focus Formation by Reticuloendotheliosis Viruses in a Quail Fibroblast Cell Line," August 25, 1982, <u>Avian Diseases</u> , Vol. 27, No. 1, pp. 261-270.	

Examiner Signature	Sharon Hunt	Date Considered	8-2-2006
-----------------------	-------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
		Filing Date	April 2, 2004		
		First Named Inventor	Peeters et al.		
		Group Art Unit	(presumed) 1648		
		Examiner Name	(presumed) S. Foley		
Sheet	4	of	8	Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Russell et al., "The Characterization of Monoclonal Antibodies to Newcastle Disease Virus," 1983, <u>J. gen. Virol.</u> , Vol. 64, pp.2069-2072.	
SH		#Wensvoort et al., "Production of Monoclonal Antibodies Against Swine Fever Virus and their use in Laboratory Diagnosis," November 14, 1986, <u>Veterinary Microbiology</u> , Vol. 12, pp.101-108.	
SH		#Chambers et al., "Molecular Cloning of Complementary DNA to Newcastle Disease Virus, and Nucleotide Sequence Analysis of the Junction between the Genes encoding the Haemagglutinin-Neuraminidase and the Large Protein," 1986, Vol. 67, pp. 475-486.	
SH		#Long et al., "Monoclonal Antibodies to Hemagglutinin-Neuraminidase and Fusion Glycoproteins of Newcastle Disease Virus: Relationship between Glycosylation and Reactivity," March 1986, <u>Journal of Virology</u> , pp. 1198-1202.	
SH		#Tessier et al., "Ligation of Single-Stranded Oligodeoxyribonucleotides by T4 RNA Ligase," 1986, Vol. 158, <u>Analytical Biochemistry</u> , pp. 171-177.	
SH		#Meulemans et al., "Protective Effects of HN and F Glycoprotein-specific Monoclonal Antibodies on Experimental Newcastle Disease," 1986, <u>Avian Pathology</u> , Vol. 15, pp. 761-768.	
SH		#Ishida et al., "Sequence of 2,617 nucleotides from the 3' end of Newcastle disease virus genome RNA and the predicted amino acid sequence of viral NP protein," 1986, <u>Nucleic Acids Research</u> , Vol. 14, No. 16, no pertinent pages listed.	
SH		#Yusoff et al., "Nucleotide sequence analysis of the L gene of Newcastle disease virus: homologies with Sendai and vesicular stomatitis viruses," April 23, 1987, pp. 3961-3976.	
SH		#Cowen et al., "The Propagation of Avian Viruses in a Continuous Cell Line (QT35) of Japanese Quail Origin," 1988, <u>Avian Diseases</u> , Vol. 32, pp. 282-297.	
SH		#Millar et al., "Nucleotide Sequence of the Fusion and Haemagglutinin-Neuraminidase Glycoprotein Genes of Newcastle Disease Virus, Strain Ulster: Molecular Basis for Variations in Pathogenicity between Strains," 1988, <u>J. gen. Virol.</u> , Vol. 69, pp. 613-620.	
SH		#Boursnell et al., "A Recombinant Fowlpox Virus Expressing the Hemagglutinin-Neuraminidase Gene of Newcastle Disease Virus (NDV) Protects Chickens against Challenge by NDV," 1990, <u>Virology</u> , Vol. 178, pp. 297-300.	
SH	✓	#Taylor et al., "Newcastle Disease Virus Fusion Protein Expressed in a Fowlpox Virus Recombinant Confers Protection in Chickens," April 1990, <u>Journal of Virology</u> , pp. 1441-1450.	

Examiner Signature	Sharon Hunt	Date Considered	8-2-2006
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
		Filing Date	April 2, 2004		
		First Named Inventor	Peeters et al.		
		Group Art Unit	(presumed) 1648		
		Examiner Name	(presumed) S. Foley		
Sheet	5	of	8	Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Vieira et al., "New pUC-derived cloning vectors with different selectable markers and DNA replication origins," 1991, <u>Gene</u> , Vol. 100, pp. 189-194.	
SH		#Antin et al., "Isolation and Characterization of an Avian Myogenic Cell Line," 1991, <u>Developmental Biology</u> , Vol. 143, pp. 111-121.	
SH		#Peeters et al., "Pseudorabies Virus Envelope Glycoproteins gp50 and gII Are Essential for Virus Penetration, but Only gII Is Involved in Membrane Fusion," February 1992, <u>Journal of Virology</u> , pp. 894-905.	
SH		#Pattnaik et al., "Infectious Defective Interfering Particles of VSV from Transcripts of a cDNA Clone," June 12, 1992, <u>Cell</u> , Vol. 69, pp. 1011-1020.	
SH		#Morgan et al., "Protection of Chickens from Newcastle and Marek's Diseases with a Recombinant Herpesvirus of Turkeys Vaccine Expressing the Newcastle Disease Virus Fusion Protein," 1992, <u>Avian Diseases</u> , Vol. 36, pp. 858-870.	
SH		#Burke Jr., A. A., "Application of an electrochemical arsine generator on a high throughput MOVPE reactor," 1992, <u>Journal of Crystal Growth</u> , Vol. 124, pp. 292-299.	
SH		#Ichihara et al., "Construction of new T Vectors for direct cloning of PCR products," 1993, <u>Gene</u> , Vol. 130, pp. 153-154.	
SH		#Steward et al., "RNA editing in Newcastle disease virus," 1993, <u>Journal of General Virology</u> , Vol. 74, pp. 2539-2547.	
SH		#Morgan et al., "Efficacy in Chickens of a Herpesvirus of Turkeys Recombinant Vaccine Containing the Fusion Gene of Newcastle Disease Virus: Onset of Protection and Effect of Maternal Antibodies," 1993, <u>Avian Diseases</u> , Vol. 37, pp. 1032-1040.	
SH		#Calain et al., "The Rule of Six, a Basic Feature for Efficient Replication of Sendai Virus Defective Interfering RNA," August 1993, <u>Journal of Virology</u> , Vol. 67, No. 8, pp. 4822-4830.	
SH		#Schnell et al., "Infectious rabies viruses from cloned cDNA," 1994, <u>The EMBO Journal</u> , Vol. 13, No. 18, pp. 4195-4203.	

Examiner Signature	Sharon Hunt	Date Considered	8-2-2006
-----------------------	-------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
		Filing Date	April 2, 2004		
		First Named Inventor	Peeters et al.		
		Group Art Unit	(presumed) 1648		
		Examiner Name	(presumed) S. Foley		
Sheet	6	of	8	Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Sh		#Whelan et al., "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones," August 1995, <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 92, pp. 8388-8392.	
Sh	✓	#Stäuber et al., "Detection of Newcastle disease virus in poultry vaccines using the polymerase chain reaction and direct sequencing of amplified cDNA," 1995, <u>Vaccine</u> , Vol. 13, No. 4, pp. 360-364.	
Sh		#Schütze et al., "Complete genomic sequence of the fish rhabdovirus infectious haematopoietic necrosis virus," 1995, <u>Journal of General Virology</u> , Vol. 76, pp. 2519-2527.	
Sh		#Radecke et al., "Rescue of measles viruses from cloned DNA," 1995, <u>The EMBO Journal</u> , Vol. 14, No. 23, pp. 5773-5784.	
Sh		#Lawson et al., "Recombinant vesicular stomatitis viruses from DNA," May 1995, <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 92, pp. 4477-4481.	
Sh		#Harty et al., "Mutations within Noncoding Terminal Sequences of Model RNAs of Sendai Virus: Influence on Reporter Gene Expression," August 1995, <u>Journal of Virology</u> , pp. 5128-5131.	
Sh		#Garcin et al., "A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus," 1995, <u>The EMBO Journal</u> , Vol. 14, No. 24, pp. 6087-6094.	
Sh		#Deng et al., "Localization of a Domain on the Paramyxovirus Attachment Protein Required for the Promotion of Cellular Fusion by Its Homologous Fusion Protein Spike," 1995, <u>Biology</u> , Vol. 209, pp. 457-469.	
Sh		#Collins et al., "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development," December 1995, <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 92, pp. 11563-11567.	
Sh		#Conzelman, Karl-Klaus, "Genetic manipulation of non-segmented negative-strand RNA viruses," 1996, <u>Journal of General Virology</u> , Vol. 77, pp. 381-389.	
		#Stäuber et al., "Detection of Newcastle disease virus in poultry vaccines using the polymerase chain reaction and direct sequencing of amplified cDNA," 1995, <u>Vaccine</u> , Vol. 13, No. 4, pp. 360-364.	duplicate

Examiner Signature	Sharon Reut	Date Considered	8-2-2006
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
		Filing Date	April 2, 2004		
		First Named Inventor	Peeters et al.		
		Group Art Unit	(presumed) 1648		
		Examiner Name	(presumed) S. Foley		
Sheet	7	of	8	Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Heckert et al., "Onset of Protective Immunity in Chicks after Vaccination with a Recombinant Herpesvirus of Turkeys Vaccine Expressing Newcastle Disease Virus Fusion and Hemagglutinin-Neuraminidase Antigens," 1996, <u>Avian Diseases</u> , Vol. 40, pp. 770-777.	
SH		#Britton et al., "Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus," 1996, <u>Journal of General Virology</u> , Vol. 77, pp. 963-967.	
SH		#Schneider et al., "Rescue of measles virus using a replication-deficient vaccinia-T7 vector," 1997, <u>Journal of Virological Methods</u> , Vol. 64, pp. 57-64.	
SH		#Lamb et al., "Paramyxoviridae: The Viruses and Their Replication," 1996, <u>Fundamental Virology, Third Edition</u> , Chapter 20, pp.577-604.	
SH		#Kant et al., "Differentiation of virulent and non-virulent strains of Newcastle disease virus within 24 hours by polymerase chain reaction," 1997, <u>Avian Pathology</u> , Vol. 26, pp.837-849.	
SH		#Hoffman et al., "An infectious Clone of Human Parainfluenza Virus Type 3," June 1997, <u>Journal of Virology</u> , pp. 4272-4277.	
SH		#Baron et al., "Rescue of Rinderpest Virus from Cloned cDNA," February 1997, <u>Journal of Virology</u> , pp. 1265-1271.	
SH		#Schirmacher et al., "Immunization With Virus-Modified Tumor Cells," December 1998, <u>Seminars in Oncology</u> , Vol. 25, No. 6, pp. 677-696.	
SH		#Kolakovsky et al., "Paramyxovirus RNA Synthesis and the Requirement for Hexamer Genome Length: the Rule of Six Revisited," February 1998, <u>Journal of Virology</u> , pp.891-899.	
SH		#Leeuw et al., "Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae," 1999, <u>Journal of General Virology</u> , Vol. 80, pp.131-136.	
SH		#Peeters et al., "Rescue of Newcastle Disease Virus from Cloned cDNA: Evidence that Cleavability of the Fusion Protein Is a Major Determinant for Virulence," June 1999, <u>Journal of Virology</u> , pp. 5001-5009.	
SH		#Oberdorfer et al., "Generation of recombinant ientogenic Newcastle disease virus from cDNA," 1999, <u>Journal of General Virology</u> , Vol. 80, pp.2987-2995.	

Examiner Signature	<i>Sharon Kent</i>	Date Considered	8-2-2006
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	April 2, 2004
		First Named Inventor	Peeters et al.
		Group Art Unit	(presumed) 1648
		Examiner Name	(presumed) S. Foley
Sheet	8	of	8
		Attorney Docket Number	2183-4646.2US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		#Philips et al., Archives of Virology, October, 1998, pp. 1993-2002, Vol. 143, No. 10.	
SH		#Sequence alignment of SEQ ID NO: 82 with GenEmbl database accession no: AJ225128 of Philips et al. submitted to database December 11, 1998.	
SH		#Kurilla et al., Virology, 1985, pp. 203-12, Vol. 145, teach SEQ ID NO: 80 (see the sequence alignment provided from the GenEmbl database accession no.	
		#Sequence alignment of SEQ ID NO: 80 with GenEmbl database accession no: U25283 of Kurilla et al. submitted to database August 2, 1993.	

Examiner Signature	Sharon Burt	Date Considered	8-2-2006
-----------------------	-------------	--------------------	----------

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/741,744

Filed: December 19, 2000

For: NEWCASTLE DISEASE VIRUS INFECTIOUS CLONES, VACCINES AND DIAGNOSTIC ASSAYS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.